These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
547 related items for PubMed ID: 18040617
1. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. Fujioka S, Misawa T, Okamoto T, Gocho T, Futagawa Y, Ishida Y, Yanaga K. J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617 [Abstract] [Full Text] [Related]
2. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP. Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014 [Abstract] [Full Text] [Related]
3. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma? Kim YC, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI, Shin JH. J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409 [Abstract] [Full Text] [Related]
4. Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer. Okusaka T, Okada S, Sato T, Wakasugi H, Saisho H, Furuse J, Ishikawa O, Matsuno S, Yokoyama S. Hepatogastroenterology; 1998 Dec; 45(21):867-72. PubMed ID: 9684148 [Abstract] [Full Text] [Related]
5. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study. Distler M, Pilarsky E, Kersting S, Grützmann R. Int J Surg; 2013 Dec; 11(10):1067-72. PubMed ID: 24161419 [Abstract] [Full Text] [Related]
6. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. Kang CM, Kim JY, Choi GH, Kim KS, Choi JS, Lee WJ, Kim BR. J Surg Res; 2007 Jun 01; 140(1):31-5. PubMed ID: 17418869 [Abstract] [Full Text] [Related]
7. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P. Eur J Surg Oncol; 2005 Mar 01; 31(2):164-9. PubMed ID: 15698733 [Abstract] [Full Text] [Related]
8. CEACAM1, a novel serum biomarker for pancreatic cancer. Simeone DM, Ji B, Banerjee M, Arumugam T, Li D, Anderson MA, Bamberger AM, Greenson J, Brand RE, Ramachandran V, Logsdon CD. Pancreas; 2007 May 01; 34(4):436-43. PubMed ID: 17446843 [Abstract] [Full Text] [Related]
9. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors. Engelen MJ, de Bruijn HW, Hollema H, ten Hoor KA, Willemse PH, Aalders JG, van der Zee AG. Gynecol Oncol; 2000 Jul 01; 78(1):16-20. PubMed ID: 10873403 [Abstract] [Full Text] [Related]
10. Receiver operating characteristic (ROC) curve analysis of the tumor markers CEA, CA 19-9 and CA 72-4 in gastric cancer. Fernández-Fernández L, Tejero E, Tieso A, Rabadán L, Munoz M, Santos I. Int Surg; 1996 Jul 01; 81(4):400-2. PubMed ID: 9127805 [Abstract] [Full Text] [Related]
11. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma. Shibata K, Iwaki K, Kai S, Ohta M, Kitano S. Pancreas; 2009 Aug 01; 38(6):619-24. PubMed ID: 19436235 [Abstract] [Full Text] [Related]
12. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Hartwig W, Strobel O, Hinz U, Fritz S, Hackert T, Roth C, Büchler MW, Werner J. Ann Surg Oncol; 2013 Jul 01; 20(7):2188-96. PubMed ID: 23247983 [Abstract] [Full Text] [Related]
13. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Chang SC. J Surg Res; 2005 Apr 01; 124(2):169-74. PubMed ID: 15820244 [Abstract] [Full Text] [Related]
14. Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer. Louhimo J, Alfthan H, Stenman UH, Haglund C. Oncology; 2004 Apr 01; 66(2):126-31. PubMed ID: 15138364 [Abstract] [Full Text] [Related]
16. Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. Park YA, Sohn SK, Seong J, Baik SH, Lee KY, Kim NK, Cho CW. J Surg Oncol; 2006 Feb 01; 93(2):145-50. PubMed ID: 16425302 [Abstract] [Full Text] [Related]
17. The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer. Kodera Y, Yamamura Y, Torii A, Uesaka K, Hirai T, Yasui K, Morimoto T, Kato T, Kito T. Am J Gastroenterol; 1996 Jan 01; 91(1):49-53. PubMed ID: 8561143 [Abstract] [Full Text] [Related]
18. [Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer]. Kokhanenko NIu, Ignashov AM, Varga EV, Polkanova MS, Aleshina LA, Kimbarovskaia AA, Osipenko SK, Lebedev EG. Vopr Onkol; 2001 Jan 01; 47(3):294-7. PubMed ID: 11544826 [Abstract] [Full Text] [Related]
19. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. Wu X, Lu XH, Xu T, Qian JM, Zhao P, Guo XZ, Yang XO, Jiang WJ. Chin J Dig Dis; 2006 Jan 01; 7(3):170-4. PubMed ID: 16808798 [Abstract] [Full Text] [Related]
20. Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer. Sato T, Nishimura G, Nonomura A, Miwa K, Miyazaki I. Hepatogastroenterology; 1999 Jan 01; 46(26):914-9. PubMed ID: 10370638 [Abstract] [Full Text] [Related] Page: [Next] [New Search]